1. Campbell JA, et al. Health economic impact of multiple sclerosis in Australia in 2021: an interim update of prevalence, costs and cost of illness from 2017 to 2021. 2023; Available from: https://www.msaustralia.org.au/wp-content/uploads/2023/02/health-economic-impact-of-multiple-sclerosis-in-australia-in-2021_final.pdf.
2. Joy JE, Johnston RB Jr, editors, Institute of Medicine (US) Committee on Multiple Sclerosis: Current Status and Strategies for the Future, in Multiple sclerosis: current status and strategies for the future. Washington (DC): National Academies Press (US). 2001
3. Lubetzki C, et al. Remyelination in multiple sclerosis: from basic science to clinical translation. Lancet Neurol. 2020;19(8):678–88.
4. Bacmeister CM, et al. Motor learning promotes remyelination via new and surviving oligodendrocytes. Nat Neurosci. 2020;23(7):819–31.
5. Keirstead HS, Blakemore WF. The role of oligodendrocytes and oligodendrocyte progenitors in CNS remyelination. Adv Exp Med Biol. 1999;468:183–97.